SCHEMBL6098249

SCHEMBL6098249

CC(C(=O)O)S(=O)(=O)N1CCC(Oc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 3/20 0.56
PROKR1 Q8TCW9 3/20 0.56
MMP13 P45452 5/20 0.54
MMP2 P08253 4/20 0.54
MMP12 P39900 1/20 0.51
EPHX2 P34913 2/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LIPE Q05469 1/20 0.48
TEAD1 P28347 1/20 0.47
ADRB2 P07550 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LIPG Q9Y5X9 2/20 0.43
LIPC P11150 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6112364 0.86 MMP13 (0.51) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL6096681 0.81 FPR2 (0.61) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL6097719 0.80 MMP13 (0.52) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL6098631 0.80 SMN1; SMN2 (0.47) EPHX2MAPTKDM4ELMNASMN1; SMN2
SCHEMBL7398293 0.80 MMP13 (0.55) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL6096540 0.80 MMP13 (0.57) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL6094533 0.79 MMP2 (0.56) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL7395651 0.77 MMP13 (0.53) FPR2PROKR1MMP13MMP2MMP12
SCHEMBL23365220 0.77 EPHX2 (0.62) FPR2PROKR1MMP13MMP2EPHX2
SCHEMBL2092945 0.76 LIPE (0.61) FPR2PROKR1MMP13MMP2MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 FPR2 2242/4885PROKR1 2895/4885MMP13 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.